Table 2.
Summary of AEs occurring in ≥ 15% of patients
| AE, n (%) | N = 74 | |
|---|---|---|
| Any grade | Grade ≥ 3 | |
| Any AE | 74 (100) | 45 (60.8) |
| Hematologic | ||
| Leukopenia | 32 (43.2) | 19 (25.7) |
| Thrombocytopenia | 31 (41.9) | 14 (18.9) |
| Anemia | 22 (29.7) | 11 (14.9) |
| Non-hematologic | ||
| Pyrexia | 68 (91.9) | 11 (14.9) |
| Increased AST | 28 (37.8) | 15 (20.3) |
| Hypotension | 14 (18.9) | 4 (5.4) |
| Increased ALT | 13 (17.6) | 0 |
| Cough | 13 (17.6) | 1 (1.4) |
| Cytokine release syndrome | 68 (91.9) | 7 (9.5)a |
| Neurotoxicity | 1 | 0 |
AE adverse event, AST aspartate transaminase, ALT, alanine aminotransferase, CRS cytokine release syndrome
a1 patient died 13 days post-treatment due to grade 5 CRS